As Monotherapy for Partial-Onset Seizures Aiming for Submission in JapanTOKYO, Nov 28, 2018 - (JCN Newswire) - Eisai Co., Ltd. announced today that based on topline results, the primary efficacy en...
Original Article: Eisai: Primary Endpoint Met in Phase III Clinical Study of Fycompa